Mike M Sathekge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3739106/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 129-138.	6.4	249
2	An Overview of Targeted Alpha Therapy with ²²⁵ Actinium and ²¹³ Bismuth. Current Radiopharmaceuticals, 2018, 11, 200-208.	0.8	248
3	Antimicrobial Peptides: Their Role as Infection-Selective Tracers for Molecular Imaging. BioMed Research International, 2014, 2014, 1-15.	1.9	151
4	Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 290-301.	6.4	144
5	Intraindividual Comparison of ¹⁸ F-PSMA-1007 and ¹⁸ F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. Journal of Nuclear Medicine, 2018, 59, 1076-1080.	5.0	140
6	Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving ²²⁵ Ac-PSMA-617 Radioligand Therapy. Journal of Nuclear Medicine, 2020, 61, 62-69.	5.0	128
7	213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1099-1100.	6.4	122
8	Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4377-4385.	6.4	114
9	Advances in imaging of tuberculosis. Current Opinion in Pulmonary Medicine, 2014, 20, 287-293.	2.6	104
10	FDG-PET Imaging in HIV Infection and Tuberculosis. Seminars in Nuclear Medicine, 2013, 43, 349-366.	4.6	98
11	PET/CT imaging of Mycobacterium tuberculosis infection. Clinical and Translational Imaging, 2016, 4, 131-144.	2.1	98
12	Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. South African Medical Journal, 2010, 100, 598.	0.6	96
13	68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 689-694.	6.4	95
14	68Ga-FAPI-PET/CT in patients with various gynecological malignancies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4089-4100.	6.4	91
15	Use of ¹⁸ F-FDG PET to Predict Response to First-Line Tuberculostatics in HIV-Associated Tuberculosis. Journal of Nuclear Medicine, 2011, 52, 880-885.	5.0	89
16	68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?. Clinical Genitourinary Cancer, 2018, 16, 392-401.	1.9	88
17	Development and Prospects of Dedicated Tracers for the Molecular Imaging of Bacterial Infections. Bioconjugate Chemistry, 2013, 24, 1971-1989.	3.6	76
18	COVID-19 pandemic: guidance for nuclear medicine departments. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1615-1619.	6.4	76

MIKE M SATHEKGE

#	Article	IF	CITATIONS
19	Preclinical Evaluation of ⁶⁸ Ga-Labeled 1,4,7-Triazacyclononane-1,4,7-Triacetic Acid-Ubiquicidin as a Radioligand for PET Infection Imaging. Journal of Nuclear Medicine, 2014, 55, 308-314.	5.0	75
20	Tuberculosis. Seminars in Nuclear Medicine, 2018, 48, 108-130.	4.6	74
21	Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 113-122.	6.4	72
22	68Ga-PSMA imaging of metastatic breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1482-1483.	6.4	67
23	Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. Journal of Nuclear Medicine, 2020, 61, 626-629.	5.0	65
24	Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy. Prostate Cancer, 2016, 2016, 1-11.	0.6	58
25	Impact of ⁶⁸ Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management. Journal of Nuclear Medicine, 2018, 59, 89-92.	5.0	58
26	Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1184-1190.	6.4	53
27	Combined 18F-Fluoride and 18F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial. Journal of Nuclear Medicine, 2013, 54, 176-183.	5.0	52
28	Peptide synthesis, characterization and 68Ga-radiolabeling of NOTA-conjugated ubiquicidin fragments for prospective infection imaging with PET/CT. Nuclear Medicine and Biology, 2014, 41, 390-400.	0.6	50
29	F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection. British Medical Bulletin, 2016, 120, 55-74.	6.9	50
30	Evaluation of thyroid nodules with technetium-99m MIBI and technetium-99m pertechnetate. Head and Neck, 2001, 23, 305-310.	2.0	48
31	Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients. Molecules, 2015, 20, 14860-14878.	3.8	48
32	Positron emission tomography in patients suffering from HIV-1 infection. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1176-1184.	6.4	45
33	Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT. Prostate, 2017, 77, 1205-1212.	2.3	45
34	Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases. Pharmaceuticals, 2017, 10, 45.	3.8	44
35	⁶⁸ Ga-NOTA-Functionalized Ubiquicidin: Cytotoxicity, Biodistribution, Radiation Dosimetry, and First-in-Human PET/CT Imaging of Infections. Journal of Nuclear Medicine, 2018, 59, 334-339.	5.0	44
36	Gallium-68 PET: A Powerful Generator-based Alternative to Infection and Inflammation Imaging. Seminars in Nuclear Medicine, 2016, 46, 436-447.	4.6	41

#	Article	IF	CITATIONS
37	Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 174-183.	6.4	41
38	Impact of FDG PET on the management of TBC treatment. Nuklearmedizin - NuclearMedicine, 2010, 49, 35-40.	0.7	41
39	Metabolic Imaging of Infection. Journal of Nuclear Medicine, 2017, 58, 1727-1732.	5.0	40
40	Monitoring Response to Therapy. Seminars in Nuclear Medicine, 2018, 48, 166-181.	4.6	40
41	Imaging fungal infections in children. Clinical and Translational Imaging, 2016, 4, 57-72.	2.1	37
42	Transient Improvement of Spinocerebellar Ataxia with Zolpidem. New England Journal of Medicine, 2004, 351, 511-512.	27.0	35
43	Prevalence and pattern of brown adipose tissue distribution of 18F-FDG in patients undergoing PET-CT in a subtropical climatic zone. Nuclear Medicine Communications, 2013, 34, 168-174.	1.1	35
44	Fluorodeoxyglucose uptake by lymph nodes of HIV patients is inversely related to CD4 cell count. Nuclear Medicine Communications, 2010, 31, 137-140.	1.1	34
45	PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review. International Journal of Molecular Sciences, 2019, 20, 4886.	4.1	33
46	Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1756-1757.	6.4	33
47	Synthesis, ⁶⁸ Ga-Radiolabeling, and Preliminary <i>In Vivo</i> Assessment of a Depsipeptide-Derived Compound as a Potential PET/CT Infection Imaging Agent. BioMed Research International, 2015, 2015, 1-12.	1.9	28
48	Accuracy of bone SPECT/CT for identifying hardware loosening in patients who underwent lumbar fusion with pedicle screws. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 349-354.	6.4	28
49	Radiopharmaceutical enhancement by drug delivery systems: A review. Journal of Controlled Release, 2018, 287, 177-193.	9.9	27
50	Global experience with PSMA-based alpha therapy in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 30-46.	6.4	27
51	Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals. Nuclear Medicine Communications, 2012, 33, 581-590.	1.1	26
52	68Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 226-234.	6.4	25
53	FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: implications for cancer staging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2010, 54, 698-703.	0.7	25
54	Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET. Nuclear Medicine Communications, 2010, 31, 311-314.	1.1	24

#	Article	IF	CITATIONS
55	Molecular imaging in musculoskeletal infections with 99mTc-UBI 29-41 SPECT/CT. Annals of Nuclear Medicine, 2018, 32, 54-59.	2.2	24
56	PSMA Theranostics: Science and Practice. Cancers, 2021, 13, 3904.	3.7	24
57	Evaluating the possible role of 68Ga-citrate PET/CT in the characterization of indeterminate lung lesions. Annals of Nuclear Medicine, 2014, 28, 523-30.	2.2	23
58	Arterial inflammation in young patients with human immunodeficiency virus infection: A cross-sectional study using F-18 FDG PET/CT. Journal of Nuclear Cardiology, 2019, 26, 1258-1265.	2.1	23
59	18F-FDG PET/CT as a Noninvasive Biomarker for Assessing Adequacy of Treatment and Predicting Relapse in Patients Treated for Pulmonary Tuberculosis. Journal of Nuclear Medicine, 2020, 61, 412-417.	5.0	23
60	A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 134-142.	6.4	23
61	A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma. Theranostics, 2021, 11, 7911-7947.	10.0	23
62	COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks. Frontiers in Immunology, 2021, 12, 752380.	4.8	23
63	Correlation between serum calcium levels and dualâ€phase ^{99m} Tcâ€sestamibi parathyroid scintigraphy in primary hyperparathyroidism. Clinical Physiology and Functional Imaging, 2012, 32, 19-24.	1.2	22
64	Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer. Current Opinion in Urology, 2020, 30, 98-105.	1.8	22
65	Preclinical Assessment of a 68Ga-DOTA-Functionalized Depsipeptide as a Radiodiagnostic Infection Imaging Agent. Molecules, 2017, 22, 1403.	3.8	21
66	PSMA expression on neovasculature of solid tumors. Histology and Histopathology, 2020, 35, 919-927.	0.7	21
67	The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2025-2033.	6.4	20
68	PET/CT features of extrapulmonary tuberculosis at first clinical presentation: a cross-sectional observational ¹⁸ F-FDG imaging study across six countries. European Respiratory Journal, 2020, 55, 1901959.	6.7	20
69	The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4067-4076.	6.4	20
70	68Ga-citrate PET/CT in tuberculosis: a pilot study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 48-55.	0.7	20
71	mCRPC Patients Receiving ²²⁵ Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis. Journal of Nuclear Medicine, 2022, 63, 1496-1502.	5.0	20
72	PET/CT scanning with a high HIV/AIDS prevalence. Transfusion and Apheresis Science, 2011, 44, 167-172.	1.0	19

MIKE M SATHEKGE

#	Article	IF	CITATIONS
73	Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Nuklearmedizin - NuclearMedicine, 2013, 52, 222-227.	0.7	19
74	Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3581-3592.	6.4	19
75	Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT. Clinical Nuclear Medicine, 2015, 40, 755-756.	1.3	18
76	Nuclear medicine services after COVID-19: gearing up back to normality. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2048-2053.	6.4	18
77	Comparison of MRI, [18F]FDG PET/CT, and 99mTc-UBI 29-41 scintigraphy for postoperative spondylodiscitis—a prospective multicenter study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1864-1875.	6.4	18
78	Gallium-68. Nuclear Medicine Communications, 2013, 34, 834-854.	1.1	17
79	The Role of PET in Monitoring Therapy in Fungal Infections. Current Pharmaceutical Design, 2018, 24, 795-805.	1.9	17
80	Past and Future of Ga-citrate for Infection and Inflammation Imaging. Current Pharmaceutical Design, 2018, 24, 787-794.	1.9	16
81	Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in Patients with Bladder Cancer. Molecular Imaging and Biology, 2022, 24, 651-658.	2.6	16
82	Clinical and brain SPECT scan response to zolpidem in patients after brain damage. Arzneimittelforschung, 2010, 60, 177-181.	0.4	15
83	The Added Value of [18F]FDG PET/CT in the Management of Invasive Fungal Infections. Diagnostics, 2021, 11, 137.	2.6	15
84	Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach. International Journal of Molecular Sciences, 2021, 22, 4109.	4.1	15
85	The potential role of 68Ga-labeled peptides in PET imaging of infection. Nuclear Medicine Communications, 2008, 29, 663-665.	1.1	14
86	Differentiation of HIV-associated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 593-595.	6.4	14
87	The Added Value of a Single-photon Emission Computed Tomography-Computed Tomography in Sentinel Lymph Node Mapping in Patients with Breast Cancer and Malignant Melanoma. World Journal of Nuclear Medicine, 2015, 14, 41.	0.5	14
88	18F-FDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma. Nuclear Medicine Communications, 2018, 39, 1005-1012.	1.1	14
89	The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases. Nuclear Medicine and Molecular Imaging, 2017, 51, 127-139.	1.0	13
90	Evaluation of a Flexible NOTA-RGD Kit Solution Using Gallium-68 from Different 68Ge/68Ga-Generators: Pharmacokinetics and Biodistribution in Nonhuman Primates and Demonstration of Solitary Pulmonary Nodule Imaging in Humans. Molecular Imaging and Biology, 2017, 19, 469-482.	2.6	13

#	Article	IF	CITATIONS
91	68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence. Nuclear Medicine Communications, 2018, 39, 179-185.	1.1	13
92	Cardiovascular disturbances in COVID-19: an updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2. BMC Cardiovascular Disorders, 2022, 22, 93.	1.7	13
93	An overview of the developments and potential applications of 68Ga-labelled PET/CT hypoxia imaging. Annals of Nuclear Medicine, 2021, 35, 148-158.	2.2	12
94	A modified technique for efficient radiolabeling of 68Ga-citrate from a SnO2-based 68Ge/68Ga generator for better infection imaging. Hellenic Journal of Nuclear Medicine, 2013, 16, 193-8.	0.3	12
95	Production of high specific activity ^{195m} Ptâ€cisplatinum at South African Nuclear Energy Corporation for Phase 0 clinical trials in healthy individual subjects. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 495-503.	1.0	11
96	Role of nuclear medicine in neuroHIV. Nuclear Medicine Communications, 2014, 35, 792-796.	1.1	11
97	18F-FDG PET/CT in the detection of asymptomatic malignant melanoma recurrence. Nuklearmedizin - NuclearMedicine, 2017, 56, 83-89.	0.7	11
98	Cryptococcoma of a transplanted kidney in a patient presenting with recurrent urinary tract infection: a case report. BMC Nephrology, 2018, 19, 94.	1.8	11
99	Sequential 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) scan findings in patients with extrapulmonary tuberculosis during the course of treatment—a prospective observational study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3118-3129.	6.4	11
100	Obstacles and Recommendations for Clinical Translation of Nanoparticle System-Based Targeted Alpha-Particle Therapy. Materials, 2021, 14, 4784.	2.9	11
101	Prognostic Value of Pre-treatment F-18 FDG PET Metabolic Metrics in Patients with Locally Advanced Carcinoma of the Anus with and without HIV Infection. Nuklearmedizin - NuclearMedicine, 2018, 57, 190-197.	0.7	11
102	Scintigraphic evaluation of craniopagus twins British Journal of Radiology, 1998, 71, 1096-1099.	2.2	10
103	Synthesis, in vitro evaluation, and ⁶⁸ Gaâ€radiolabeling of <scp>CDP</scp> 1 toward <scp>PET</scp> / <scp>CT</scp> imaging of bacterial infection. Chemical Biology and Drug Design, 2017, 90, 572-579.	3.2	10
104	Apoptosis Imaging in Oncology by Means of Positron Emission Tomography: A Review. International Journal of Molecular Sciences, 2021, 22, 2753.	4.1	10
105	Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 427-435.	6.4	10
106	Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis. Nuklearmedizin - NuclearMedicine, 2019, 58, 371-378.	0.7	10
107	What impact can fluorine-18 fluorodeoxyglucose PET/computed tomography have on HIV/AIDS and tuberculosis pandemic?. Nuclear Medicine Communications, 2009, 30, 255-257.	1.1	9
108	Samarium oxide as a radiotracer to evaluate the in vivo biodistribution of PLGA nanoparticles. Journal of Nanoparticle Research, 2015, 17, 1.	1.9	9

MIKE M SATHEKGE

#	Article	IF	CITATIONS
109	Xeroderma pigmentosum in South Africa: Evidence for a prevalent founder effect. British Journal of Dermatology, 2019, 181, 1070-1072.	1.5	9
110	[68Ca]Ga-Pentixafor for PET Imaging of Vascular Expression of CXCR-4 as a Marker of Arterial Inflammation in HIV-Infected Patients: A Comparison with 18F[FDG] PET Imaging. Biomolecules, 2020, 10, 1629.	4.0	9
111	Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. Cancers, 2021, 13, 3607.	3.7	9
112	South African guidelines for receptor radioligand therapy (RLT) with Lu-177-PSMA in prostate cancer. South African Journal of Surgery, 2019, 57, 45-51.	0.2	9
113	Spinal Tuberculosis Evaluated by Means of 18F-FDG PET/CT: Pilot Study. The Open Nuclear Medicine Journal, 2014, 6, 6-11.	0.2	9
114	Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research. Ecancermedicalscience, 2020, 14, 1093.	1.1	9
115	Impact of optimized PET imaging conditions on 18F-FDG uptake quantification in patients with apparently normal aortas. Journal of Nuclear Cardiology, 2021, 28, 1349-1359.	2.1	8
116	Radionuclide imaging of inflammation in atherosclerotic vascular disease among people living with HIV infection: current practice and future perspective. European Journal of Hybrid Imaging, 2019, 3, 5.	1.5	8
117	Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1414-1433.	6.4	8
118	Imaging of Pulmonary Tuberculosis with 18F-Fluoro-Deoxy-Glucose and 18F-Ethylcholine. The Open Nuclear Medicine Journal, 2014, 6, 17-21.	0.2	8
119	Appropriate indications for positron emission tomography/computed tomography, 2015. South African Medical Journal, 2015, 106, 105.	0.6	7
120	Fluorodeoxyglucose Positron Emission Tomography integrated with computed tomography in carcinoma of the cervix: Its impact on accurate staging and the predictive role of its metabolic parameters. PLoS ONE, 2019, 14, e0215412.	2.5	7
121	The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report. Nuclear Medicine and Molecular Imaging, 2021, 55, 136-140.	1.0	7
122	Radionuclide Imaging of Fungal Infections and Correlation with the Host Defense Response. Journal of Fungi (Basel, Switzerland), 2021, 7, 407.	3.5	7
123	Rheumatic Fever. Clinical Nuclear Medicine, 2015, 40, 250-252.	1.3	6
124	Imaging latent tuberculosis infection with radiolabeled nitroimidazoles. Clinical and Translational Imaging, 2016, 4, 157-159.	2.1	6
125	Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma. Nuclear Medicine Communications, 2017, 38, 222-227.	1.1	6
126	Characterization of FDG PET Images Using Texture Analysis in Tumors of the Gastro-Intestinal Tract: A Review. Biomedicines, 2020, 8, 304.	3.2	6

#	Article	IF	CITATIONS
127	The Association of Tumor Burden by 18F-FDG PET/CT and Survival in Vulvar Carcinoma. Clinical Nuclear Medicine, 2021, 46, 375-381.	1.3	6
128	Pattern of Prostate Cancer Recurrence Assessed by 68Ga-PSMA-11 PET/CT in Men Treated with Primary Local Therapy. Journal of Clinical Medicine, 2021, 10, 3883.	2.4	6
129	Radionuclide Imaging of Invasive Fungal Disease in Immunocompromised Hosts. Diagnostics, 2021, 11, 2057.	2.6	6
130	Fluorine-18-fluoroethylcholine PET/CT in the detection of prostate cancer: a South African experience. Hellenic Journal of Nuclear Medicine, 2015, 18, 53-9.	0.3	6
131	A Prospective Investigation of Tumor Hypoxia Imaging with 68Ga-Nitroimidazole PET/CT in Patients with Carcinoma of the Cervix Uteri and Comparison with 18F-FDG PET/CT: Correlation with Immunohistochemistry. Journal of Clinical Medicine, 2022, 11, 962.	2.4	6
132	Can positron emission tomography work in the African tuberculosis epidemic?. Nuclear Medicine Communications, 2011, 32, 241-244.	1.1	5
133	Appropriate indications for positron emission tomography/computed tomography: College of Nuclear Physicians of the Colleges of Medicine of South Africa. South African Medical Journal, 2015, 105, 894.	0.6	5
134	Comparison of rubidium-82 myocardial blood flow quantification with coronary calcium score for evaluation of coronary artery stenosis. Nuclear Medicine Communications, 2016, 37, 197-206.	1.1	5
135	<i>In Vitro</i> Functional Quality Characterization of NOTA-Modified Somatropins. Analytical Chemistry, 2017, 89, 2764-2772.	6.5	5
136	Work-based assessment: A critical element of specialist medical training. South African Medical Journal, 2017, 107, 728.	0.6	5
137	Use of a Sentinel Lymph Node Biopsy Algorithm in a South African Population of Patients With Cervical Cancer and High Prevalence of Human Immunodeficiency Virus Infection. International Journal of Gynecological Cancer, 2018, 28, 1432-1437.	2.5	5
138	68Ga-PSMA: a One-stop Shop in Radioactive lodine Refractory Thyroid Cancer?. Nuclear Medicine and Molecular Imaging, 2019, 53, 442-445.	1.0	5
139	Practical Considerations When Interpreting FDG PET/CT Imaging for Staging and Treatment Response Assessment in Melanoma Patients. Seminars in Nuclear Medicine, 2021, 51, 544-553.	4.6	5
140	Molecular imaging of cardiovascular inflammation and infection in people living with HIV infection. Clinical and Translational Imaging, 2020, 8, 141-155.	2.1	5
141	Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine. Current Pharmaceutical Design, 2014, 20, 2308-2318.	1.9	5
142	Reversible myocardial perfusion defects in patients not suffering from obstructive epicardial coronary artery disease as assessed by coronary angiography. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 325-335.	0.7	5
143	[68ÂGa]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2445-2446.	6.4	5
144	Immune reconstitution inflammatory syndromeâ€associated Graves disease in HIVâ€infected patients: clinical characteristics and response to radioactive iodine therapy. HIV Medicine, 2021, 22, 907-916.	2.2	4

#	Article	IF	CITATIONS
145	Association of hemodynamic response during dipyridamole stress testing with 99mTc-MIBI SPET myocardial perfusion image findings. Hellenic Journal of Nuclear Medicine, 2013, 16, 181-5.	0.3	4
146	Development of nuclear medicine in Africa. Clinical and Translational Imaging, 2022, 10, 101-111.	2.1	4
147	First results and experience with PRRT in South Africa. World Journal of Nuclear Medicine, 2018, 17, 86-93.	0.5	4
148	Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients. Frontiers in Oncology, 2022, 12, 819790.	2.8	4
149	Diagnostic utility of F-FDG PET/CT in fever of unknown origin among patients with end-stage renal disease treated with renal replacement therapy. Hellenic Journal of Nuclear Medicine, 2019, 22, 70-75.	0.3	4
150	The Use of 18F-FDG PET/CT Metabolic Parameters in Predicting Overall Survival in Patients Undergoing Restaging for Malignant Melanoma. Diagnostics, 2022, 12, 595.	2.6	4
151	A comparison of the diagnostic performance of F-PSMA-1007 and GA-PSMA-11 in the same patients presenting with early biochemical recurrence Hellenic Journal of Nuclear Medicine, 2021, 24, 178-185.	0.3	4
152	[68Ga]Ga-NODAGAZOL uptake in atherosclerotic plaques correlates with the cardiovascular risk profile of patients. Annals of Nuclear Medicine, 2022, 36, 684-692.	2.2	4
153	Association between plasma homocysteine and myocardial SPECT abnormalities in patients referred for suspected myocardial ischaemia. Cardiovascular Journal of Africa, 2012, 23, 313-317.	0.4	3
154	Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1922-1924.	6.4	3
155	Effect of AIDS on Women Who Have Sex-Determined Health Issues. Seminars in Nuclear Medicine, 2014, 44, 489-498.	4.6	3
156	A randomized-controlled study of a modified technique to reduce extracardiac activity in myocardial perfusion imaging. Nuclear Medicine Communications, 2017, 38, 21-28.	1.1	3
157	Burkitt lymphoma and cavernous sinus syndrome with breast uptake on 18F-FDG-PET/CT. Medicine (United States), 2017, 96, e8687.	1.0	3
158	Renal osteodystrophy presenting as a metabolic superscan on F-18 FDG PET/CT. Medicine (United States), 2017, 96, e8471.	1.0	3
159	FDG PET/CT for evaluating systemic arterial inflammation induced by anthracycline-based chemotherapy of Hodgkin lymphoma. Medicine (United States), 2020, 99, e23259.	1.0	3
160	Statin Intake and All-Cause Mortality among Older Nursing Home Residents. Gerontology, 2022, 68, 407-411.	2.8	3
161	Towards Facile Radiolabeling and Preparation of Gallium-68-/Bismuth-213-DOTA-[Thi8, Met(O2)11]-Substance P for Future Clinical Application: First Experiences. Pharmaceutics, 2021, 13, 1326.	4.5	3
162	Imaging dysregulated calcium homeostasis in acute myocardial infarction with [68ÂGa]Ga-NODAGAZOL. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 417-418.	6.4	3

#	Article	IF	CITATIONS
163	CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Nuklearmedizin - NuclearMedicine, 2014, 53, 131-138.	0.7	3
164	Positron emission tomography in the prediction of inflammation in children with human immunodeficiency virus related bronchiectasis. Hellenic Journal of Nuclear Medicine, 2012, 15, 23-7.	0.3	3
165	The College of Nuclear Physicians of South Africa Practice Guidelines on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours. South African Journal of Surgery, 2018, 56, 55-64.	0.2	3
166	Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma. Cancers, 2022, 14, 1821.	3.7	3
167	The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml. Nuklearmedizin - NuclearMedicine, 2022, 61, 120-129.	0.7	3
168	<scp> ⁶⁸ Ga </scp> â€nitroimidazole <scp>PET</scp> / <scp>CT</scp> imaging of hypoxia in tuberculosis: A case series. Journal of Medical Radiation Sciences, 0, , .	1.5	3
169	PET/CT-positive brown tumour - a potentially misleading finding in the evaluation of a patient for malignant primary tumour or metastases. South African Journal of Radiology, 2007, 11, 103.	0.3	2
170	Synthesis of Iâ€131 labelled 4â€iodophenylacetic acid. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 54-58.	1.0	2
171	Blood-brain barrier integrity in a zolpidem-responder patient. South African Medical Journal, 2012, 102, 790.	0.6	2
172	68Gallium-Arginine-Glycine-Aspartic Acid and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Chondroblastic Osteosarcoma of the Skull. Nuclear Medicine and Molecular Imaging, 2017, 51, 271-273.	1.0	2
173	Reply: Molecular Imaging of Bacteria in Patients Is an Attractive Fata Morgana, Not a Realistic Option. Journal of Nuclear Medicine, 2018, 59, 717-717.	5.0	2
174	Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report. Current Problems in Cancer Case Reports, 2021, 3, 100038.	0.1	2
175	Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases. Current Radiopharmaceuticals, 2021, 14, 242-258.	0.8	2
176	18F-FDG PET/CT imaging of vulva cancer recurrence: A comparison of PET-derived metabolic parameters between women with and without HIV infection. Nuklearmedizin - NuclearMedicine, 2020, 59, 419-427.	0.7	2
177	The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma. World Journal of Nuclear Medicine, 2019, 18, 123-126.	0.5	2
178	First Results and Experience with PRRT in South Africa. World Journal of Nuclear Medicine, 2018, 17, 86-93.	0.5	2
179	Correlation Between CT Features of Active Tuberculosis and Residual Metabolic Activity on End-of-Treatment FDG PET/CT in Patients Treated for Pulmonary Tuberculosis. Frontiers in Medicine, 2022, 9, 791653.	2.6	2
180	The Utility of Metabolic Parameters on Baseline F-18 FDG PET/CT in Predicting Treatment Response and Survival in Paediatric and Adolescent Hodgkin Lymphoma. Journal of Clinical Medicine, 2021, 10, 5979.	2.4	2

#	Article	IF	CITATIONS
181	68Ga-PSMA-11 PET/CT Initial Staging in Black and White South African Males with ISUP Grade Group 1 and 2 Prostate Adenocarcinoma. Biomedicines, 2022, 10, 882.	3.2	2
182	Radionuclide imaging of hypoxia: Where are we now? Special attention to cancer of the cervix uteri Hellenic Journal of Nuclear Medicine, 2021, 24, 247-261.	0.3	2
183	PET/CT features of a novel gallium-68 labelled hypoxia seeking agent in patients diagnosed with tuberculosis: a proof-of-concept study. Nuclear Medicine Communications, 2022, Publish Ahead of Print, .	1.1	2
184	Pheochromocytomas/Paragangliomas and two cases. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2007, 49, 42-45.	0.6	1
185	Letter From the Guest Editor. Seminars in Nuclear Medicine, 2016, 46, 370-372.	4.6	1
186	Salivary Gland Activity Obscures Mandibular Metastasis of Prostate Carcinoma on 68Ga–Prostate-Specific Membrane Antigen PET. Clinical Nuclear Medicine, 2018, 43, 106-109.	1.3	1
187	Biological Characterisation of Somatropin-Derived Cryptic Peptides. International Journal of Peptide Research and Therapeutics, 2019, 25, 1019-1031.	1.9	1
188	Comparison of DOTA and NODAGA as chelates for 68Ga-labelled CDP1 as novel infection PET imaging agents. Journal of Radioanalytical and Nuclear Chemistry, 2019, 322, 629-638.	1.5	1
189	Preclinical assessment of ⁶⁸ Gaâ€PSMAâ€617 entrapped in a microemulsion delivery system for applications in prostate cancer PET/CT imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 332-345.	1.0	1
190	Adjunctive Use of Statins for COVID-19. Journal of Clinical Medicine, 2021, 10, 1407.	2.4	1
191	Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid. Current Radiopharmaceuticals, 2012, 5, 356-362.	0.8	1
192	Detection of Extensive Metastases from Anaplastic Thyroid Cancer by F-18 FDG-PET/CT. The Open Nuclear Medicine Journal, 2011, 3, 1-6.	0.2	1
193	Ensuring effective and sustainable radionuclide delivery and its impact on the development of nuclear medicine in the developing world with special reference to Nigeria. World Journal of Nuclear Medicine, 2019, 18, 2.	0.5	1
194	Diagnostic value of sentinel lymph node scintigraphy and 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the detection of metastatic lymph nodes in patients with early-stage cervical cancer. World Journal of Nuclear Medicine, 2020, 19, 240.	0.5	1
195	18F-FDG-PET/CT imaging of uterine cervical cancer recurrence in women with and without HIV infection. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, , .	0.7	1
196	Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa. Hellenic Journal of Nuclear Medicine, 2017, 20, 128-133.	0.3	1
197	I-123 Uptake by Intrathoracic Stomach. Clinical Nuclear Medicine, 2005, 30, 42.	1.3	0
198	Impact of scintimammography in management of breast cancer. South African Journal of Radiology, 2006, 10, 8.	0.3	0

#	Article	IF	CITATIONS
199	Pioneering PET/CT services in South Africa. Nuclear Medicine Communications, 2007, 28, 235-237.	1.1	0
200	Metastatic calcification as a result of extensive bone metastases in a paediatric patient with Parameningeal Embryonal Rhabdomyosarcoma. South African Journal of Radiology, 2008, 12, 10.	0.3	0
201	Protein-losing enteropathy demonstrated on Tc-99m HSA. South African Journal of Radiology, 2008, 12, 36.	0.3	0
202	Reply: 18F-FDG PET/CT as a Sensitive and Early Treatment Monitoring Tool: Will This Become the Major Thrust for Its Clinical Application in Infectious and Inflammatory Disorders?. Journal of Nuclear Medicine, 2012, 53, 165.2-166.	5.0	0
203	The optimal TSH level necessary for successful radioiodine ablation of differentiated thyroid carcinoma, as well as the time to reach this level, is a work in progress. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1270-1271.	6.4	0
204	Prof. Alpheus Mabose Segone. South African Medical Journal, 2018, 108, 253.	0.6	0
205	225Ac-PSMA-617 in Chemotherapy-naive Patients with Advanced Prostate Cancer. Journal of Medical Imaging and Radiation Sciences, 2019, 50, S30.	0.3	0
206	PET imaging in HIV patients. , 2021, , .		0
207	The clinical utility of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in guiding myocardial revascularisation. Clinical and Translational Imaging, 0, , 1.	2.1	0
208	Cardiac Devices Infection. , 2021, , 233-259.		0
209	Impulsivity Imaging. , 2014, , 583-620.		0
210	Imaging of the Antidepressant Drug Response Using SPECT and PET. , 2014, , 325-345.		0
211	Nuclear Medicine Imaging of Sport Injuries of the Wrist, Hand and Fingers. , 2015, , 525-548.		0
212	Imaging in the Developing World. , 2017, , 239-247.		0
213	Kaposi sarcoma: an unusual cause of intussusception in an adult patient. South African Journal of Surgery, 2018, 56, 30-31.	0.2	0
214	PET/CT in Immunodeficiency Disorders. , 2018, , 15-27.		0
215	Imaging Tuberculosis and AIDS Associated Infections. , 2020, , 237-257.		0

#	Article	IF	CITATIONS
217	The impact of prior therapies on overall survival in mCRPC patients receiving Lu-PSMA-617 therapy. A WARMTH retrospective multicenter trial. , 2020, 59, .		0
218	Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatropin case. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 105-114.	0.7	0
219	Impulsivity Imaging. , 2021, , 773-816.		0
220	FDC-PET in Treatment Response Assessment of Tuberculosis. , 2020, , 133-144.		0
221	Nuclear Medicine Imaging Techniques in Melanoma. , 2020, , 665-683.		0
222	Gallium Imaging of Infection and Inflammation. , 2022, , 103-123.		0
223	Radionuclide Therapy of Skin Cancers and Bowen's Disease Using A Specially Designed Rhenium Cream. , 2021, , .		0
224	Nuclear medicine therapy of prostate cancer: State of the art and future perspectives. , 2021, , .		0
225	A comparison of F-FDG PET/CT findings in HIV positive compared to HIV negative patients with recurrent cervical cancer. Hellenic Journal of Nuclear Medicine, 2017, 20 Suppl, 71-79.	0.3	0
226	Symmetric breasts metastatic prostate cancer shown by Ga-PSMA PET/CT scan. Hellenic Journal of Nuclear Medicine, 2019, 22, 76.	0.3	0
227	Superficial Brachytherapy of Nonmelanoma Skin Cancer with Rhenium-188. World Journal of Nuclear Medicine, 2022, , .	0.5	0
228	Utilizing 18F-FDG PET/CT Metabolic Parameters to Predict Progression-Free and Overall Survival in Patients with Malignant Melanoma. World Journal of Nuclear Medicine, 2022, , .	0.5	0